Hookipa Pharma and Gilead: Strategic Bet on Viral Cure Vaccines

Overview

Hookipa Pharma is a clinical-stage biotechnology company developing immunotherapies using novel arenavirus vector platforms. The company has two main technologies:

VaxWave (non-replicating vectors): These vectors induce strong antibody and T-cell responses without provoking neutralizing immunity, allowing repeated administration.
TheraT (replicating vectors): Designed to replicate within host cells and elicit exceptionally strong CD8+ T-cell responses. Particularly effective for targeting chronic infections and tumors.

Gilead Sciences, a global leader in antivirals, acquired Hookipa’s HB-400 and HB-500 programs in 2025. These vaccines are therapeutic candidates targeting hepatitis B and HIV, respectively. The acquisition reflects Gilead’s strategic commitment to advancing curative therapies for chronic viral infections, building on years of collaboration between the two companies.

The Acquired Programs

HB-400 (Hepatitis B therapeutic vaccine): Uses alternating LCMV and PICV arenavirus vectors to deliver HBV antigens. Phase 1 trials were led by Gilead and completed enrollment by late 2024. Preclinical results indicated substantial antigen clearance and strong T-cell responses.
HB-500 (HIV therapeutic vaccine): Targets HIV-1 using the same alternating vector strategy. The vaccine was being tested in a Hookipa-led Phase 1b trial initiated in mid-2024. Gilead is now assuming development control and likely integrating it into its HIV cure pipeline.

Both programs originated from a collaboration dating back to 2018, with a 2022 renewal involving $15 million upfront and $5 million equity investment. Gilead’s takeover in 2025 includes full asset rights and clinical strategy realignment.

Deal Structure and Financials

Gilead paid $3 million upfront and agreed to another $7 million in milestone-based tranches, totaling up to $10 million in direct payment for asset transfer. Hookipa retains the rights to receive up to $422.5 million in clinical, regulatory, and commercial milestones, plus royalties on future sales. The structure minimizes Gilead’s upfront risk while preserving significant upside for Hookipa if the programs succeed.

Additionally, Gilead already held a 19.4% equity stake in Hookipa following a $21.25 million investment in 2023, showing long-term alignment and trust in the technology.

Strategic Rationale for Gilead

Therapeutic Fit: Gilead dominates the antiviral space with leading drugs for HIV and HBV. However, functional cures remain elusive. These vaccines aim to eliminate infected cells through T-cell-driven immunity, a necessary next step beyond viral suppression.

Pipeline Integration: Gilead’s HBV pipeline includes capsid inhibitors, siRNAs, and checkpoint inhibitors. For HIV, the company is testing latency-reversing agents, long-acting injectables, and broadly neutralizing antibodies. The acquired vaccines complement these therapies.

Cost Efficiency: The modest acquisition cost allows Gilead to acquire two unique assets with high potential without disrupting its R&D budget. If successful, the programs could define next-generation standards in HBV and HIV treatment.

The arenavirus vectors provide a robust immune response unmatched by prior therapeutic vaccines. Their ability to be re-administered without neutralization makes them ideal for chronic diseases requiring multiple immune stimuli.

Industry and Competitive Landscape

Hepatitis B Cure Efforts:

Current treatments suppress viral replication but rarely achieve HBsAg loss. Functional cure rates remain under 10%.
Competitor setbacks: Vir Biotechnology and GSK terminated trials after underwhelming results. J&J and Roche are also reevaluating HBV pipelines.
Vaccitech remains a leading vaccine competitor with VTP-300 (ChAdOx1/MVA-based). Early trials showed some HBsAg reductions and a few cures. Gilead’s HB-400 aims for stronger T-cell immunity and more robust outcomes.

HIV Cure Landscape:

No therapeutic vaccine has achieved durable ART-free remission. Approaches like “kick and kill” or “block and lock” require effective immune clearance agents.
AELIX Therapeutics and other small players are pursuing T-cell vaccines but with limited clinical validation.
Gilead’s acquisition positions it as the most serious player in this area, combining HB-500 with its existing arsenal (e.g. lenacapavir, bNAbs).

Differentiation: Arenavirus vectors elicit much stronger CD8+ responses than adenovirus or DNA vectors and do not require complex delivery platforms. Hookipa’s alternating vector approach avoids vector immunity and enables repeated boosting, crucial for achieving durable antiviral effects.

Development Timeline and Forecast

HB-400: Initial Phase 1 readouts expected in 2025. If antigen reduction is confirmed, Phase 2 trials could launch in 2026. Gilead likely to test HB-400 in combination with its siRNA or checkpoint inhibitors.

HB-500: Gilead may halt or redesign the current Phase 1b and initiate new combination trials integrating latency reversal. If immune activation is confirmed, the program may advance to larger remission studies by 2026–27.

Success Scenarios:

Partial or full functional cure demonstrated.
Gilead leads Phase 3 pivotal trials by 2028.
Hookipa receives milestone payments and platform validation.

Failure Scenarios:

Immune response insufficient or safety issues arise.
Programs discontinued. Gilead’s financial loss minimal. Hookipa pivots entirely to oncology.

Intermediate Outcomes:

The vaccines are used adjunctively to enhance other therapies.
Combination therapies reach market even if the vaccines alone do not suffice.

Impact on Hookipa

Removes financial burden of infectious disease trials.
Extends runway to focus on oncology programs like:
Eseba-vec (HB-200): Phase 2, HPV16+ cancers.
HB-300: Prostate cancer (PSA/PAP targeting).
HB-700: Multi-mutant KRAS cancers.

Hookipa maintains rights to these assets, with eseba-vec showing especially promising data in combination with pembrolizumab.

Analyst and Market Reactions

Hookipa’s share price increased post-deal announcement.
Analysts called the transaction a strategic de-risking and praised the milestone-heavy structure.
Some estimates suggest Hookipa could see over 1000% upside if milestones are hit and oncology assets succeed.

Gilead’s strategy of acquiring early-stage innovation through flexible structures (as with Kite, Arcus, and Immunomedics) continues. This transaction fits that model: low initial outlay, full control, and massive upside if validated.

Comparable Deals

Jazz–Redx (2024): $10M upfront for KRAS program; up to $870M milestones.
Merck–Modifi (2024): $30M upfront; $1.3B in milestones.
Gilead–Pionyr: Option-based deal in immuno-oncology.

Such structures reflect biotech’s financial pressures and pharma’s appetite for focused, risk-mitigated innovation access.

HOOKIPA PHARMA
(HOOK : NASDAQ)

Gilead’s acquisition of HB-400 and HB-500 reflects a calculated, long-term commitment to curing HBV and HIV. For Hookipa, the deal secures short-term stability and long-term opportunity through retained royalties and redirected oncology focus. If successful, the arenavirus platform could set a new paradigm in therapeutic vaccination, offering finite, curative treatment paths for two of the world’s most enduring viral challenges.
Even if only one of the programs succeeds, this modest investment could yield transformative results—scientifically, commercially, and medically. For both companies, the bet is asymmetric: limited downside, extraordinary potential upside.

deep researched with AI